DDInter1747 DDInter785
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fostamatinib has been identified as a potential therapeutic for controlling acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 through its ability to modulate the SYK kinase.[A235008, A235013, A235018]
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tofacitinib
Fostamatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Fostamatinib {u} may lead to a major life threatening interaction when taken with {v} Berotralstat
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Fostamatinib may lead to a major life threatening interaction when taken with Clarithromycin
Fostamatinib may lead to a major life threatening interaction when taken with Berotralstat